Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with GenentechAccesswire • 05/25/21
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare ConferenceAccesswire • 05/20/21
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/17/21
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/17/21
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateAccesswire • 05/17/21
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021Accesswire • 05/10/21
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificAccesswire • 04/26/21
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual MeetingAccesswire • 04/10/21
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/30/21
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/30/21
Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate UpdateAccesswire • 03/30/21
Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R) (tucatinib) in Gastric Cancer, and Strategic Equity IAccesswire • 03/25/21
Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021Accesswire • 03/23/21
Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 03/05/21
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/04/20
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20